Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 25, 2019-- Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news